Hay MP[au] - Search Results

Year	Number of Results
1994	1
1995	2
1996	3
1999	3
2000	1
2003	6
2004	3
2005	3
2006	4
2007	2
2008	2
2009	2
2010	3
2011	5
2012	3
2013	3
2014	6
2016	3
2017	2
2018	3
2019	7
2020	3
2021	1
2022	2
2023	2
2024	0

1

Targeting growth hormone function: strategies and therapeutic applications.

Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK. Lu M, et al. Among authors: hay mp. Signal Transduct Target Ther. 2019 Feb 8;4:3. doi: 10.1038/s41392-019-0036-y. eCollection 2019. Signal Transduct Target Ther. 2019. PMID: 30775002 Free PMC article. Review.

2

Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs.

Jackson RK, Liew LP, Hay MP. Jackson RK, et al. Among authors: hay mp. Clin Oncol (R Coll Radiol). 2019 May;31(5):290-302. doi: 10.1016/j.clon.2019.02.004. Epub 2019 Mar 8. Clin Oncol (R Coll Radiol). 2019. PMID: 30853148 Review.

3

Targeting hypoxia in cancer therapy.

Wilson WR, Hay MP. Wilson WR, et al. Among authors: hay mp. Nat Rev Cancer. 2011 Jun;11(6):393-410. doi: 10.1038/nrc3064. Nat Rev Cancer. 2011. PMID: 21606941 Review.

4

Hypoxia-Activated Prodrugs of PERK Inhibitors.

Liew LP, Singleton DC, Wong WW, Cheng GJ, Jamieson SMF, Hay MP. Liew LP, et al. Among authors: hay mp. Chem Asian J. 2019 Apr 15;14(8):1238-1248. doi: 10.1002/asia.201801826. Epub 2019 Jan 29. Chem Asian J. 2019. PMID: 30615821

5

Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides.

Bonnet M, Hong CR, Wong WW, Liew LP, Shome A, Wang J, Gu Y, Stevenson RJ, Qi W, Anderson RF, Pruijn FB, Wilson WR, Jamieson SMF, Hicks KO, Hay MP. Bonnet M, et al. Among authors: hay mp. J Med Chem. 2018 Feb 8;61(3):1241-1254. doi: 10.1021/acs.jmedchem.7b01678. Epub 2018 Jan 11. J Med Chem. 2018. PMID: 29253343

6

Hypoxia-directed drug strategies to target the tumor microenvironment.

Hay MP, Hicks KO, Wang J. Hay MP, et al. Adv Exp Med Biol. 2014;772:111-45. doi: 10.1007/978-1-4614-5915-6_6. Adv Exp Med Biol. 2014. PMID: 24272357 Review.

7

Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers.

Liew LP, Shome A, Wong WW, Hong CR, Hicks KO, Jamieson SMF, Hay MP. Liew LP, et al. Among authors: hay mp. Molecules. 2023 May 31;28(11):4457. doi: 10.3390/molecules28114457. Molecules. 2023. PMID: 37298933 Free PMC article.

8

Recent developments in the design of bioreductive drugs.

Denny WA, Wilson WR, Hay MP. Denny WA, et al. Among authors: hay mp. Br J Cancer Suppl. 1996 Jul;27:S32-8. Br J Cancer Suppl. 1996. PMID: 8763842 Free PMC article. Review. No abstract available.

9

ZD-0473 AstraZeneca.

Hay MP. Hay MP. Curr Opin Investig Drugs. 2000 Oct;1(2):263-6. Curr Opin Investig Drugs. 2000. PMID: 11249584

10

Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer.

Lee TW, Lai A, Harms JK, Singleton DC, Dickson BD, Macann AMJ, Hay MP, Jamieson SMF. Lee TW, et al. Among authors: hay mp. Cancers (Basel). 2020 Dec 12;12(12):3743. doi: 10.3390/cancers12123743. Cancers (Basel). 2020. PMID: 33322840 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

71 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year